| Summary: | CADTH undertook reanalyses to address limitations that included bevacizumab as a relevant comparator, applying equal treatment discontinuation, adjusting vision impairment costs, and applying a pooled, long-term treatment effect. Using the CADTH base-case reanalyses, brolucizumab would not be considered cost-effective treatment at a willingness-to-pay (WTP) threshold of $50,000 per quality-adjusted life-year (QALY). The probability of brolucizumab being considered the most cost-effective intervention was 0% at a threshold of $50,000 per QALY (and even at a threshold of $100,000 per QALY). Price reductions can improve the cost-effectiveness of brolucizumab in patients with neovascular age-related macular degeneration (nAMD). At a WTP threshold of $50,000 per QALY, a respective price reduction of 85% is required for brolucizumab to be considered cost-effective compared to bevacizumab. No price reduction would be required for brolucizumab if bevacizumab was unavailable as a treatment option. While some uncertainties remain in the model, it is highly unlikely that brolucizumab would be considered a cost-effective intervention relative to bevacizumab based on the efficacy estimates and price submitted by the sponsor
|
|---|